Perimenopause is not menopause — and the depression risk window is real

Perimenopause is the transition phase that leads into menopause. It typically begins in a woman’s mid-40s, though it can start earlier or later, and it can last anywhere from a few years to a full decade. During this window, ovarian hormone production becomes erratic. Estrogen and progesterone do not simply decline in a smooth line. They swing — sometimes sharply — and those swings drive a cluster of symptoms ranging from hot flashes and sleep disruption to mood changes that can be hard to distinguish from clinical depression.

The crucial point: perimenopausal depression is not a softer version of major depression. It is major depression. A 2011 analysis from the Study of Women’s Health Across the Nation (SWAN) by Bromberger and colleagues, published in Archives of General Psychiatry, found perimenopausal women had approximately two times the risk of a major depressive episode compared to premenopausal women, even after controlling for prior depression history.

Major medical bodies now recognize this. The North American Menopause Society’s 2022 hormone therapy position statement and 2023 nonhormone therapy position statement together identify perimenopause as a window of increased mood-disorder risk and support individualized treatment that may include antidepressants, hormone therapy, or both. ACOG practice guidance on menopause similarly identifies major depressive disorder as more common during the menopausal transition and recommends standard MDD treatment alongside symptom management.

So when a patient walks in and says, “I think this is just my hormones,” we take that seriously — and we also take seriously the possibility that what is happening is a real depressive episode. Both can be true.

Why estrogen and glutamate are connected

Most people associate estrogen with reproduction. In the brain, it does much more than that. Estrogen is a powerful neuromodulator that influences serotonin, dopamine, and — importantly for this conversation — the glutamate system.

Glutamate is the brain’s primary excitatory neurotransmitter. It binds to NMDA receptors and AMPA receptors and shapes how neurons fire, communicate, and form new connections. Estrogen helps keep this system in balance. It modulates NMDA receptor density, supports synaptic plasticity, and tunes the excitatory tone of brain regions involved in mood, including the prefrontal cortex and hippocampus.

When estrogen swings during perimenopause, the glutamate system can get destabilized. Animal and human research over the past two decades has shown that estrogen withdrawal is associated with measurable changes in glutamate signaling, NMDA receptor function, and synaptic plasticity in mood-relevant brain regions. That is the same system ketamine works on.

Ketamine is an NMDA receptor antagonist that produces a rapid surge in synaptic plasticity through what researchers call the glutamate-AMPA-BDNF cascade. In short, ketamine briefly blocks NMDA receptors, which paradoxically triggers a burst of AMPA-mediated activity and brain-derived neurotrophic factor (BDNF) release. That cascade appears to support the formation of new synaptic connections in the prefrontal cortex — the same region where chronic stress and depression have been shown to thin connections out.

The convergence is not coincidence. The system perimenopause destabilizes is the system ketamine is best known for repairing. That is why the question of ketamine for perimenopausal depression is biologically reasonable, even though the targeted clinical-trial evidence is still developing.

What the MDD ketamine evidence implies for this group

To be clear: there is no large randomized controlled trial of IV ketamine specifically for perimenopausal depression. The cohort has not been studied as a separate clinical group. What we do have is a substantial and consistent body of evidence for ketamine in major depressive disorder generally, and the underlying mechanism does not change because of a patient’s reproductive stage.

A 2013 randomized controlled trial by Murrough and colleagues, published in the American Journal of Psychiatry, compared a single IV ketamine infusion to midazolam (an active placebo) in 73 patients with treatment-resistant depression. At 24 hours, 64% of the ketamine group met response criteria, compared to 28% of the midazolam group. That two-fold difference held up across multiple secondary endpoints and helped establish ketamine’s rapid antidepressant signal as a real biological effect rather than a non-specific placebo response.

Subsequent randomized trials in the 2020s have replicated and extended these findings. Repeated-dose IV protocols produce response rates that remain meaningful weeks after the last infusion in a substantial portion of patients. The FDA approval of intranasal esketamine (Spravato) for treatment-resistant depression and for MDD with acute suicidal ideation rests on this same evidence base.

Ketamine itself is FDA-approved as an anesthetic; its use for depression in this IV form is off-label. Esketamine is the FDA-approved psychiatric option. The off-label framing does not mean the evidence is weak. It means the regulatory pathway has not caught up to clinical practice for racemic IV ketamine.

For a perimenopausal patient with major depression, the implication is straightforward: the evidence base that supports ketamine for MDD generally applies. There is no biological reason to expect a perimenopausal patient to respond worse than the broader MDD population, and there are theoretical reasons — the estrogen-glutamate connection — to think this group may be particularly suited to a treatment that acts directly on the glutamate system. That is a hypothesis, not a proof. We say so plainly.

Where hormone therapy, SSRIs, and ketamine fit

Treatment for perimenopausal depression is not a winner-takes-all decision. The most thoughtful clinicians treat it as a layered conversation, and the layers are not mutually exclusive.

Hormone therapy can address vasomotor symptoms (hot flashes, night sweats) and may improve mood for some women, particularly those whose depressive symptoms track tightly with hormonal fluctuation. NAMS supports individualized hormone therapy in appropriate candidates. This is a conversation to have with a gynecologist or menopause-trained clinician, not with us. We are not a hormone therapy clinic.

SSRIs and SNRIs remain first-line for major depression in most guidelines, including ACOG’s. They work for many women. They take four to eight weeks to reach full effect, and roughly one-third of patients do not respond adequately to the first medication tried. For women who do well on an SSRI, that is the right answer. For those who do not, options matter.

IV ketamine tends to be considered when standard antidepressants have not worked, when the depressive symptoms are severe enough that a four-to-eight-week wait feels unworkable, or when a patient prefers a treatment that acts on a different mechanism. None of these tracks excludes the others. We have patients who are on an SSRI, on hormone therapy, and pursuing ketamine in parallel, with their prescribing providers coordinating care. That is normal.

What we do not do: we do not tell patients to stop or change medications. Decisions about SSRIs, hormone therapy, or any other prescribed treatment belong with the prescribing clinician. Our role is to add a tool to the toolkit, not to swap one out.

What a session feels like in this cohort

A standard IV ketamine session at our clinic runs about 40 minutes for the infusion itself, with additional time before and after for monitoring and recovery. Plan on roughly 90 minutes door-to-door. You will need a driver.

The experience during the infusion is gentle for most patients. There is typically a sense of bodily lightness, sometimes a mild dissociative quality — a feeling of watching thoughts move past rather than being trapped inside them. For many perimenopausal patients, that distance from rumination is itself a relief. The depressive thought loops that have felt inescapable for months can briefly, palpably loosen.

If you have not done this before, our overview of what to expect at your first infusion walks through the practical details — arrival, vitals, the IV placement, what the room looks like, what we ask you to bring. Private rooms are climate-adjustable, which matters for patients dealing with hot flashes. Layered blankets, water within reach, and the option to take off or add layers mid-session are all part of how we set up.

Side effects are typically mild and resolve quickly. The most common are mild dissociation during the infusion, occasional nausea, and a transient bump in blood pressure. We monitor for all of these. Marla Peterson, CRNA, oversees every infusion and is on-site throughout, providing anesthesia-level monitoring — continuous pulse oximetry, blood pressure, and heart rate tracking. Our broader safety overview details exactly what that looks like.

Sleep, hot flashes, and ketamine response

One of the most common questions we get from perimenopausal patients is about sleep. The honest answer is both/and. Most patients see sleep improve as their depression lifts, because depression and insomnia feed each other, and breaking the depressive loop tends to release the sleep loop along with it. Some patients report vivid dreams in the days after a session, particularly for the first one or two infusions. That tends to settle.

Ketamine is not a sleep medication, however, and it will not fix every cause of perimenopausal sleep disruption. Hot flashes that wake you up at 3 a.m. are a hormonal phenomenon. Ketamine does not directly treat them. If sleep is your primary concern, our article on ketamine and sleep walks through the research in detail, and we strongly encourage a conversation with your gynecologist about hot flash management in parallel.

Hot flashes during a session itself are something we have seen and accommodate routinely. Temperature regulation, a layered blanket, hydration before and after — small things that matter. Sessions are private, so patients can adjust comfort without the awkwardness of shared infusion bays.

How we approach perimenopausal patients in Nashville

Our approach starts with a full clinical conversation. We want to understand the timeline of your symptoms, your reproductive stage, your treatment history, and what other clinicians are involved in your care. We will ask about prior depressive episodes, current medications, hormone therapy status, and what you have already tried.

If ketamine seems like a reasonable option, we will lay out a typical induction protocol — usually six infusions over two to three weeks — and discuss what maintenance might look like for your situation. The induction is where most of the work happens. Maintenance, if needed, is individualized and often spaced weeks or months apart depending on response.

Cost is transparent. IV ketamine for depression is an off-label, self-pay treatment in nearly all cases. At Music City Ketamine, sessions are $475 each. We say so up front, in the first conversation, before any commitment is made.

If you are exploring this for the first time, our depression treatment overview may be useful, as may our article on ketamine for postpartum depression — the closest cohort in the published literature, another life stage where hormonal transitions intersect with major depression.

Honest expectations

We want to be straightforward about what ketamine can and cannot do in this context.

If perimenopause and depression have arrived in your life at the same time, you are not imagining the connection. The biology is real, the risk window is real, and there are options worth exploring carefully with clinicians who have seen this combination before.